0.00Open0.05Pre Close0 Volume137 Open Interest20.00Strike Price0.00Turnover3277.90%IV11.80%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0601Delta0.0638Gamma452.40Leverage Ratio-46.5253Theta0.0000Rho-27.19Eff Leverage0.0001Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet